Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4040-4047

  Maio, Michele ^a   Covre, Alessia ^a   Fratta, Elisabetta ^b   Di Giacomo, Anna Maria ^a   Taverna, Pietro ^c   Natali, Pier Giorgio ^d   Coral, Sandra ^a   Sigalotti, Luca ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLOPHOSPHAMIDE; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GUADECITABINE; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; CHROMATIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL DEATH; CHROMATIN STRUCTURE; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DNA SEQUENCE; DRUG MECHANISM; EPIGENETICS; ESOPHAGUS CANCER; GENE EXPRESSION REGULATION; GENE MUTATION; GENOME IMPRINTING; GENOMIC INSTABILITY; GLIOBLASTOMA; HISTONE MODIFICATION; HUMAN; IMMUNE EVASION; IMMUNOGENIC CELL DEATH; IMMUNOMODULATION; KIDNEY CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MEDULLOBLASTOMA; METASTATIC COLORECTAL CANCER; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NEUROECTODERM TUMOR; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; UTERINE TUBE CARCINOMA; X CHROMOSOME INACTIVATION; ANIMAL; CHEMISTRY; CHROMATIN; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; MUTATION; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MICE; MUTATION; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84942853841     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2914     Document Type: Article

References (48)

1. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27: 5932-43.
2. Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 2012; 22: 350-8.
3. McDermott D, Lebbe C, Hodi F.S., Maio M., Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014; 40:1056-64.
4. Maio M, Grob JJ, Aamdal S, Bondarenko I., Robert C, Thomas L, et al Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33: 1191-6.
5. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010; 70: 27-56.
6. Turner BM. Histone acetylation and an epigenetic code. Bioessays 2000; 22:836-45.
7. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 2005; 19: 563-73.
8. Vakoc CR, Mandat SA, Olenchock B.A., Blobel GA. Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin. Mol Cell 2005; 19: 381-91.
9. Zhao Q, Rank G, Tan Y.T., Li H., Moritz RL, Simpson RJ, et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling his-tone and DNA methylation in gene silencing. Nat Struct Mol Biol 2009; 16: 304-11.
10. Tachibana M, Matsumura Y, Fukuda M., Kimura H, Shinkai Y. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J 2008; 27: 2681-90.
11. Sigalotti L, Fratta E, Coral S., Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 2014; 142: 339-50.
12. West AC, Johnstone RW New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-9.
13. Campbell RM, Tummino PJ Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 2014; 124: 64-9.
14. Navada SC, Steinmann J, Lubbert M., Silverman LR. Clinical development of demethylating agents in hematology. J Clin Invest 2014; 124: 40-6.
15. Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun 2014; 455: 58-69.
16. Richon VM. Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics 2010; 2: 457-65.
17. Coral S, Covre A, Nicolay H.J., Parisi G., Rizzo A, Colizzi F, et al Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer 2012; 107: 1116-24.
18. Cameron EE, Bachman KE, Myohanen S, Herman J.G., Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-7.
19. Murakami T, Sato A, Chun N.A., Hara M., Naito Y, Kobayashi Y, et al Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008; 128: 1506-16.
20. Srivastava P, Paluch BE, Matsuzaki J, James S.R., Collamat-Lai G, Karbach J, et al Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 2014; 38: 1332-41.
21. Yang H, Lan P, Hou Z., Guan Y, Zhang J, Xu W., et al. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer 2015; 112: 112-21.
22. Coral S, Parisi G, Nicolay H.J., Colizzi F., Danielli R, Fratta E, et al Immunomodulatory activity of SGI-110, a 5-aza-2' -deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother 2013; 62: 605-14.
23. Fratta E, Sigalotti L, Colizzi F., Covre A, Nicolay HJ, Danielli R, et al Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 2010; 223: 352-8.
24. Armeanu S, Bitzer M, Lauer U.M., Venturelli S., Pathil A, Krusch M, et al Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-9.
25. Li H, Chiappinelli KB, Guzzetta A.A., Easwaran H., Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014; 5: 587-98.
26. Schrump DS, Fischette MR, Nguyen D.M., Zhao M., Li X, Kunst TF, et al Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-85.
27. Sigalotti L, Altomonte M, Colizzi F., Degan M, Rupolo M, Zagonel V., et al. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 2003; 101: 4644-6; discussion 4645-6
28. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S., McSkeane T, Ryan G, et al Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-18.
29. Kroemer G, Galluzzi L, Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
30. Sonnemann J, Gressmann S, Becker S., Wittig S, Schmudde M, Beck JF The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol 2010; 66:611-6.
31. West AC, Mattarollo SR, Shortt J, Cluse L.A., Christiansen AJ, Smyth MJ, et al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 2013; 73: 7265-76.
32. Guillot F, Boutin B, Blanquart C., Fonteneau JF, Robard M, Gregoire M, et al Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. Vaccine 2011; 29: 5534-43.
33. Postow MA, Callahan MK, Wolchok JD Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-82.
34. Garcia JS, Jain N, Godley LA An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther 2010; 3: 1-13.
35. Kozar K, Kaminski R, Switaj T., Oldak T, Machaj E, Wysocki P.J., et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 2003; 9: 3124-33.
36. Simova J, Pollakova V, Indrova M, Mikyskova R, Bieblova J, Stepanek I, et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. Br J Cancer 2011; 105: 1533-41.
37. Shen L, Ciesielski M, Ramakrishnan S., Miles KM, Ellis L, Sotomayor P, et al Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 2012; 7: e30815.
38. Sun JZ, Gao L, Wang W., Du N, Yang J, Wan L., et al. Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic Tlymphocyte function in a mousemammary model. Biomed Res Int 2013; 2013: 196894.
39. Lisiero DN, Soto H, Everson R.G., Liau LM, Prins RM. The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. J Immunother Cancer 2014; 2: 8.
40. Vo DD, Prins RM, Begley J.L., Donahue TR, Morris LF, Bruhn KW, et al Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009; 69: 8693-9.
41. Guo ZS, Hong JA, Irvine K.R., Chen GA, Spiess PJ, Liu Y, et al De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006; 66:1105-13.
42. Calabro L, Morra A, Fonsatti E., Cutaia O, Fazio C, Annesi D., et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015; 3: 301-9.
43. Covre A, Coral S, Nicolay H., Parisi G, Fazio C, Colizzi F., et al. Anti-tumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology 2015 Apr 2. [Epub ahead of print].
44. Covre A, Coral S, Di Giacomo A, Taverna P, Azab M., Maio M. Epigenetics meets immune checkpoints. Semin Oncol 2015; 42: 506-13.
45. Kim K, Skora AD, Li Z, Liu Q., Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014; 111: 11774-9.
46. Christiansen AJ, West A, Banks K.M., Haynes NM, Teng MW, Smyth MJ, et al Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A 2011; 108:4141-6.
47. Plimack ER, Desai JR, Issa J.P., Jelinek J., Sharma P, Vence LM, et al A phase I study of decitabine with pegylated interferon alpha-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs 2014; 32: 969-75.
48. Odunsi K, Matsuzaki J, James S.R., Mhawech-Fauceglia P, Tsuji T, Miller A., et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014; 2: 37-49.